Gastroenterology and Hepatology From Bed to Bench最新文献

{"title":"Larger fruit consumption helps constipation patients: socioeconomic analysis from 2005 - 2010 NHANES matched cohorts.","authors":"Thanathip Suenghataiphorn, Pojsakorn Danpanichkul, Narathorn Kulthamrongsri, Kanokphong Suparan, Tuntanut Lohawatcharagul, Natchaya Polpichai, Jerapas Thongpiya","doi":"10.22037/ghfbb.v18i1.2997","DOIUrl":"10.22037/ghfbb.v18i1.2997","url":null,"abstract":"<p><strong>Aim: </strong>We aimed to utilize a large-scale database to better understand its efficacy in this subpopulation group.</p><p><strong>Background: </strong>Constipation is one of the most common gastrointestinal complaints in the United States whose alleviation often requires multiple interventions and behavioral changes. Fruits are often one of the dietary recommendations for constipated patients, but their efficacy remains mixed.</p><p><strong>Methods: </strong>We examined the nationwide cross-sectional study in the 2006 - 2010 National Health and Nutrition Examination Survey (NHANES) database. Patients over 20 years old were stratified into fruit-consumption and non-fruit-consumption groups. We excluded patients who had intestinal disease, colon cancer, celiac disease, and were pregnant. We used multivariable logistic regression to determine the association between fruit intake and constipation status as recorded in the database.</p><p><strong>Results: </strong>A total of 12,192 patients were included in our study. The average age was 50.5, and 49.56% of the population are Caucasians, followed by 26.43% of Hispanics; 9.84% had constipation; and 70.04% had fruit consumption. After adjusting for age, gender, ethnicity, education, marital status, poverty ratio, body mass index, food healthy index, physical activity, supplemental usage, medications, smoking, and alcohol usage, patients who had fruit consumption had a lower odd of constipation (aOR 0.83, 95%CI (0.72, 0.95), p=0.008). Further, patients who had larger fruit intake were likely to be less constipated. Post-propensity score matching revealed similar statistically significant.</p><p><strong>Conclusion: </strong>Fruit intake, as well larger amount of fruit intake, was associated with lesser odds of constipation. Additional investigations in the fruit subtype, as well as the longitudinal relationship, are required to understand this relationship.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"70-81"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring drug repurposing as a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD): identification of potential targets and pathways.","authors":"Yalda Khazaei-Poul, Sara Ziayifard, Ava Rashtchian, Abbas Pyriae, Seyed Ali Ziai","doi":"10.22037/ghfbb.v18i2.3071","DOIUrl":"10.22037/ghfbb.v18i2.3071","url":null,"abstract":"<p><strong>Aim: </strong>This study investigates drug repurposing as a viable approach identifying existing pharmacological agents that could be applied to NAFLD management.</p><p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is a prevalent and complex liver condition affecting approximately 25% of the global population, with significant links to metabolic disorders such as obesity and type 2 diabetes. Despite its high burden, no approved therapies currently exist for NAFLD, underscoring the need for effective treatments.</p><p><strong>Methods: </strong>We utilized two publicly available datasets (GSE126848 and GSE130970) to identify differentially expressed genes (DEGs) and constructed a protein-protein interaction (PPI) network using Cytoscape. Hub and bottleneck (H&B) genes were identified and further analyzed for pathway enrichment using DAVID and KEGG. Drug candidates were identified through the Connectivity Map (CMap) platform, focusing on compounds with counter-gene signatures.</p><p><strong>Results: </strong>Pathway analysis highlighted critical pathways involved in NAFLD pathogenesis, including the AGE-RAGE and Rap1 signaling pathways. Several promising repurposed drugs, such as WYE-354 and Triciribine, were identified, targeting key mechanisms like lipid metabolism and inflammation.</p><p><strong>Conclusion: </strong>This study suggests that drug repurposing may accelerate the development of effective NAFLD therapies, although further clinical validation is needed to confirm the therapeutic potential of these findings.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"230-245"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies.","authors":"Keyvan Heydari, MohamadAli Rahnavard, Sulmaz Ghahramani, Aref Hoseini, Reza Alizadeh-Navaei, Sajjad Rafati, Maede Raei, MohammadAli Vahidipour, Fatemeh Salehi, Farzaneh Motafeghi, Sina Neshat, Mahmood Moosazadeh, Mohammad Yousefi, Ava Pourali, Kimia Rasouli, Shiva Shokrirad, Parisa Lotfi, Seyed-Ahmad Beladi, Mohammad Hadizadeh Neisanghalb, Fateme Sheydaee, Sabra Moghadam","doi":"10.22037/ghfbb.v18i2.3105","DOIUrl":"10.22037/ghfbb.v18i2.3105","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to systematically review the global epidemiology of Inflammatory Bowel Disease (IBD).</p><p><strong>Background: </strong>IBD is a global concern, and its incidence is rising worldwide.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, and Web of Science from 1 January 2000 to 14 July 2022 using MeSH keywords. All population-based studies that reported the incidence or prevalence of IBD, Crohn's disease (CD), or ulcerative colitis (UC) were included. Random effect models were applied to combine the prevalence and incidence.</p><p><strong>Results: </strong>Findings from 215 studies were analyzed. The global prevalence rates of IBD, CD, and UC were 229.7 per 100,000 (95% confidence interval: 212.4 to 247.0), 84.2 (78.5 to 89.9), and 120.4 (110.5 to 130.3), and the incidence was 9.7 per 100,000 person-years (9.2 to 10.2), 4.0 (3.8 to 4.2), and 5.0 (4.6 to 5.3), respectively. The highest IBD and CD incidence were seen in Oceania (21.3 [12.9 to 29.7] and 12.2 [8.5 to 15.9], respectively), while the highest incidence of UC was reported in North America (9.8 [6.7 to 12.8]). According to the pooled prevalence, Europe had the highest prevalence rates of IBD and UC (348.4 [315.2 to 381.5] and 198.6 [181.6 to 215.6], respectively), whereas Oceania was the continent with the highest CD prevalence (173.6 [151.8 to 195.4]).</p><p><strong>Conclusion: </strong>Our findings showed that the incidence and prevalence of IBD in both developed and developing nations are mounting. Special focus should be placed on understanding and managing pediatric CD cases, necessitating targeted research and early interventions.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"132-146"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of supraglottic airway vs. infraglottic airway in endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis.","authors":"Vanio L J Antunes, Tulio L Correa, Matthew Antony Manoj, Matheus Vanzin Fernandes, Cynthia Florêncio de Mesquita, Otávio Cosendey Martins, Natalia Junkes Milioli, Stefano Baraldo, Sara Amaral, Julio Pereira-Lima","doi":"10.22037/ghfbb.v18i1.3044","DOIUrl":"10.22037/ghfbb.v18i1.3044","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of supraglottic airway (SGA) vs. infraglottic airway (IGA) in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).</p><p><strong>Background: </strong>To optimize patient outcomes by improving airway control, various airway techniques have been employed for sedation during ERCP. However, there is uncertainty about the noninferiority of SGA devices compared to IGA.</p><p><strong>Methods: </strong>We performed a systematic review in PubMed, Embase, and Cochrane Library databases, searching for randomized and non-randomized studies comparing SGA vs. IGA in patients undergoing ERCP and reporting at least one of the outcomes of interest. The primary outcomes were procedure time, incidence of hypoxia, and blood staining events. Statistical analyses were performed using R language 4.3.1. Odds ratio (OR) was used for binary outcomes and mean difference (MD) for continuous outcomes with their respective 95% confidence interval (CI). Heterogeneity was assessed using the Cochran Q test and I² statistics.</p><p><strong>Results: </strong>The study comprised 1 randomized controlled trial (RCT) and 3 observational studies involving 280 patients. Among them, 160 were allocated to the SGA group and 120 to the IGA group. When comparing procedure times, there was no statistically significant difference between SGA and IGA (MD -1.51 minutes; 95% CI -6.10 to 3.09 minutes; p = 0.52; I² = 62%). Regarding blood staining, statistical significance favored IGA over SGA (OR 2.67; 95% CI 1.12 to 6.41, p = 0.027; I² = 0%).</p><p><strong>Conclusion: </strong>No statistically significant difference in procedure time was observed between SGA and IGA. However, IGA exhibited a favorable outcome regarding reduced blood staining compared to SGA. Further studies comparing similar outcomes are necessary to assess such associations better.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"32-38"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of circulating uric acid in gastrointestinal cancers, a systematic review and meta-analysis.","authors":"Rozita Khodashahi, Mahdieh Jajroudi, Gordon A Ferns, Mohsen Aliakbarian, Mohammad-Hassan Arjmand","doi":"10.22037/ghfbb.v18i1.2965","DOIUrl":"10.22037/ghfbb.v18i1.2965","url":null,"abstract":"<p><strong>Aim: </strong>Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).</p><p><strong>Background: </strong>There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.</p><p><strong>Methods: </strong>Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).</p><p><strong>Results: </strong>A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.</p><p><strong>Conclusion: </strong>Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"21-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antisense RNAs (asRNAs) as key players in gallbladder cancer progression: a bioinformatics analysis.","authors":"Monika Rajput, Ruhi Dixit, Manoj Pandey, Vijay Kumar Shukla","doi":"10.22037/ghfbb.v18i2.3002","DOIUrl":"10.22037/ghfbb.v18i2.3002","url":null,"abstract":"<p><strong>Aim: </strong>This study reports differential expression of Antisense RNAs (asRNAs) by analyzing transcriptomic profiles in gallbladder cancer (GBC).</p><p><strong>Background: </strong>asRNAs play crucial roles in developing various tumors. However, the presence and biological mechanism of asRNAs in GBC development are still unknown.</p><p><strong>Methods: </strong>Differentially expressed asRNAs (DE-asRNAs) were systematically identified from RNA sequencing data from ten GBC patients. Functional enrichment analysis was performed, followed by the identification of mRNAs targeted by asRNAs and the construction of a gene regulatory network of asRNAs targeting mRNAs.</p><p><strong>Results: </strong>Of the 891 asRNAs identified, 17 DE-asRNAs were statistically significant. Out of 17, 12 asRNAs were upregulated, and five asRNAs were downregulated. Functional enrichment analysis showed their role in methylation and developmental processes. Of the 17 asRNAs, 14 are novel (UNC5B-AS1, SLC2A1-AS1, BBOX1-AS1, SOX21-AS1, ELFN1-AS1, TRPM2-AS, DNAH17-AS1, DCST1-AS1, VPS9D1-AS1, MIR1-1HG-AS1, HAND2-AS1, PGM5P4-AS1, PGM5P3-AS1, and MAGI2-AS). Enrichment analysis of asRNAs with target mRNAs showed enrichment in biological regulation and developmental processes involved in the PI3K, p53, apoptosis, and VEGF signaling pathways.</p><p><strong>Conclusion: </strong>This study identified 14 asRNAs for the first time and showed that asRNAs targeting mRNAs strongly associated with tumor development in GBC through the PI3KCA and TP53 pathways.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"216-229"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resting functional magnetic resonance images of the brain in functional gastrointestinal diseases: a concise review of the literature.","authors":"Parsia Noori Mirtaheri, Saba Mehrtabar, Reza Shah Hosseini, Kianoush Shahryari, SeyedAbbas Pakmehr, Arash Rahimi, Sourena Mohammad Hashem, Seyed Amirabbas Shahidi Marnani, Shaghayegh Karami, Mahsa Sadeghi, Yeganeh Azhdary Moghaddam, Aida Azhdari Moghaddam, Niloofar Deravi, Mahsa Asadi Anar","doi":"10.22037/ghfbb.v18i2.2987","DOIUrl":"10.22037/ghfbb.v18i2.2987","url":null,"abstract":"<p><p>Functional gastrointestinal disorders (FGID) are prevalent illnesses associated with diminished quality of life and increased healthcare utilization. These conditions influence gut sensitivity, motility, microbiota, immunological function, and nervous processing in the brain. Chronic symptoms, including pain and dyspepsia, are exacerbated by maladaptive patient behaviors, stress, and co-morbidity. Studies of functional neuroimaging reveal increased brain responses in regions associated with gut sensory processing and salient cues, altered central regulation of endocrine and autonomic nerve responses, and aberrant connections in pain processing and the default mode network. This neuroimaging helps us understand the pathophysiology and outcomes of patients better. From the standpoint of brain connection, research in this area can further our understanding of the central pathophysiology of FGID and pave the way for the objective diagnosis and development of novel therapeutics for FGID. Prospective Neuroimaging research may change from brain mapping to clinical prognosis prediction due to technological advances in machine learning algorithms used in imaging. The usefulness and revelations of functional brain imaging are highlighted in this review, along with the areas that require development and, lastly, recommendations for future research.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"164-176"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of primary sclerosing cholangitis (PSC) in Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders: systematic review and meta-analysis.","authors":"Ehsaneh Taheri, Behzad Hatami, Fatemeh Baghalha, Sara Ashtari, Zahra Nosrati, Mohammad Reza Zali","doi":"10.22037/ghfbb.v18i1.3046","DOIUrl":"10.22037/ghfbb.v18i1.3046","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the prevalence of primary sclerosing cholangitis (PSC) among Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders.</p><p><strong>Background: </strong>PSC is a rare and chronic liver disease characterized by inflammation, fibrosis, and intra- and/or extrahepatic bile duct structure.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted. The Web of Science, Scopus, Pubmed, Embase, Google Scholar, and local databases, including the IranDoc, IranMedex, SID, and MagIran databases, were searched for studies published before 6th February 2023 for the prevalence of PSC among Iranian adults.</p><p><strong>Results: </strong>In total, 22 articles involving 19,747 Iranian participants were included in this meta-analysis. The overall pooled prevalence of PSC was 8% (95% CI: 5%-12%). Additionally, the prevalence of PSC stratified by gender was calculated based on four studies (n = 1402). The pooled prevalence of PSC was estimated to be 20% (95% CI: 11-31%) in males and 12% (95% CI: 3-38%) in females. The pooled prevalence of PSC was 6% (95% CI: 4-9%) in patients with IBD and 14% (95% CI: 8-23%) in patients with liver transplantation (LT).</p><p><strong>Conclusion: </strong>The pooled prevalence of PSC was 8% in Iranian adults, and the prevalence was greater in males than in females.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"10-20"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A gluten-free diet has a different effect on the iron profile of celiac disease and non-celiac gluten-sensitive patients with idiopathic iron deficiency anaemia.","authors":"Mehrdad Haghazali, Mohammad Rostami-Nejad, Abbas Hajfathali, Luca Elli, Mohsen Norouzinia, Hamid Asadzadeh-Aghdaei, Amir Sadeghi, Mahshid Akhavan Rahnama, Azadeh Anbarlou, Haniye Ghasiyari, Hamid Mohaghegh-Shalmani, Mostafa Rezaei-Tavirani, Masiha Amiri, Mohammad Reza Zali","doi":"10.22037/ghfbb.v18i2.3139","DOIUrl":"10.22037/ghfbb.v18i2.3139","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to assess the impact of a six-week gluten-free diet (GFD) on the iron profiles of patients with non-celiac gluten sensitivity (NCGS) and CD.</p><p><strong>Background: </strong>Iron-deficiency anaemia (IDA) is a significant clinical feature of gluten-related disorders, especially Celiac disease (CD).</p><p><strong>Methods: </strong>The study included 29 CD patients (mean age 40.28 ± 15.57 years) and 29 NCGS patients (mean age 30.31 ± 7.78 years) presenting with IDA who were enrolled in the study during 2023-2024. Haemoglobin, serum iron, serum ferritin, total iron-binding capacity (TIBC), and transferrin saturation (TSAT) levels were assessed at the beginning and after six weeks of GFD. HLA typing was conducted using the Real-time PCR-based SYBR Green method.</p><p><strong>Results: </strong>Ferritin levels significantly increased in both CD and NCGS groups after the GFD, from 43.7807 to 50.5279 ng/mL and 23.0862 to 42.9910 ng/mL, respectively. Moreover, serum iron and TSAT levels significantly increased in the NCGS group, from 64.8034 to 81.3466 μg/dL and 19.29 ± 11.70 to 23.99 ± 9.05, respectively (p = 0.003).</p><p><strong>Conclusion: </strong>The most frequent symptoms in CD and NCGS patients were bloating/bone disease (62.1%) and bone disease (37.9%), respectively. GFD was effective in improving IDA in both CD and NCGS patients. Further research is necessary to assess the therapeutic effect of GFD in patients with gastrointestinal symptoms and IDA.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 2","pages":"211-215"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving etiologies of liver transplantation: a trend analysis from 2020 to 2024 at the main center of Iran.","authors":"Mohamad Jamalinia, Kamran Bagheri Lankarani, Seyed Ali Malek-Hosseini","doi":"10.22037/ghfbb.v18i1.3035","DOIUrl":"10.22037/ghfbb.v18i1.3035","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to analyze trends in the etiologies of liver transplants at Abu Ali Sina Hospital, Shiraz, Iran, from 2020 to 2024.</p><p><strong>Background: </strong>Liver transplantation (LT) is a crucial treatment for end-stage liver disease (ESLD). Over time, the etiologies leading to LT have evolved due to changes in disease prevalence, advancements in medical treatments, and public health interventions.</p><p><strong>Methods: </strong>Etiologies of LT were categorized into nine groups: acute liver failure, autoimmune disorders, alcoholic steatohepatitis, liver cancer, vascular, metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, metabolic disorders, and others. Trend analysis was performed using Python 3.12 programming language with appropriate libraries.</p><p><strong>Results: </strong>A total of 1579 patients, 59.9% male with a mean age of 45.12 years (SD: 13.52), were analyzed. Autoimmune disorders emerged as the leading cause of LT, increasing from 32.2% in 2020 to 40.6% in 2024 (p-trend = 0.039). Viral hepatitis cases decreased significantly from 18.1% to 3.0% (p-trend = 0.033). Liver cancer became the third leading cause in 2021, replacing viral hepatitis, while MASH consistently remained the second leading cause.</p><p><strong>Conclusion: </strong>The significant shifts in LT etiologies underscore the success of public health interventions in reducing the burden of viral-related ESLD. Additionally, the findings highlight the need for ongoing research into the prevention, early diagnosis, and management of autoimmune liver diseases, MASH, and liver cancer. These findings provide critical insights for clinicians and policymakers to enhance liver disease management and allocate resources effectively.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"115-119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}